Welcome to our dedicated page for TELA Bio SEC filings (Ticker: TELA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TELA Bio, Inc. filings document a commercial-stage medical technology business centered on soft-tissue reconstruction and the OviTex product portfolio for hernia repair and abdominal wall reconstruction. Form 8-K reports cover operating and financial results, revenue updates, Regulation FD disclosures, material agreements, debt and equity capital structure, and other material events tied to the company's medical technology operations.
Proxy materials and governance-related 8-Ks record board composition, director appointments and resignations, executive compensation matters, stockholder meeting proposals, inducement and equity-award practices, and Nasdaq listing-compliance disclosures for TELA common stock listed on the Nasdaq Global Market.
TELA Bio reported strong revenue growth but continued losses for the fourth quarter and full year 2025. Fourth quarter revenue reached $20.9 million, up 18% from 2024, with gross margin of 65.9% and a reduced operating loss of $6.6 million. Full-year revenue was $80.3 million, a 16% increase, and gross margin improved to 67.7%, while the net loss widened slightly to $38.8 million. Cash and cash equivalents were $50.8 million at December 31, 2025, against long-term debt of $55.7 million. Management highlighted its largest quarterly revenue to date, 88 revenue-generating representatives, and expressed confidence in achieving at least 8% revenue growth in 2026 while progressing toward profitability without raising additional capital.
TELA Bio, Inc. reported that it received a notice from Nasdaq stating its common stock has closed below the required $1.00 per share minimum bid price for 30 consecutive business days, putting the company out of compliance with Nasdaq Listing Rule 5450(a)(1) for the Nasdaq Global Market.
The stock will continue trading under the symbol “TELA” for now, and the notice has no immediate effect on the current listing. TELA Bio has until September 14, 2026 to regain compliance, which would occur if the closing bid price stays at or above $1.00 for at least 10 consecutive business days.
If compliance is not regained by that date, Nasdaq may grant an additional 180-day period if TELA transfers to the Nasdaq Capital Market and meets its other listing standards. Failure to regain compliance after these periods could lead to delisting, though the company would have the right to appeal. TELA Bio plans to monitor its share price and explore options to resolve the deficiency.
TELA Bio, Inc. Chief Medical Officer Howard N. Langstein filed an initial statement of holdings. He directly holds 71,347 shares of common stock and a stock option covering 72,750 shares at an exercise price of $0.7830 per share, expiring on February 18, 2036. The option vests 25% on February 18, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, contingent on continued service.
TELA Bio, Inc. director and CEO Antony Koblish reported a mix of equity awards and tax-related share dispositions. On February 20, 2026, he was granted 176,000 shares of common stock as restricted stock units that will vest in four equal annual installments beginning on February 20, 2027, subject to his continued service. He also received a stock option for 261,000 shares, vesting 25% on February 20, 2027 and the remaining 75% in equal monthly installments over the following 36 months, also subject to continued service. On February 21, 23, and 24, 2026, a total of 28,?? shares of common stock were disposed of at prices between $0.7174 and $0.7852 per share to cover withholding taxes upon RSU vesting, with shares withheld by the issuer rather than sold in open-market transactions.
TELA Bio, Inc. Chief Business Officer Gregory A. Firestone reported a mix of equity grants and tax-related share dispositions. On February 20, 2026, he was granted 55,000 stock options and 37,000 shares of common stock in the form of restricted stock units that vest in four equal annual installments beginning February 20, 2027, subject to his continued service. The option vests 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments over the next 36 months, also conditioned on continued service. On February 21 and 23, 2026, a total of 5,541 common shares were withheld by the company at prices of $0.7174 and $0.7660 per share to satisfy tax liabilities upon RSU vesting, leaving him with 139,307 common shares held directly, which includes 1,058 shares acquired under the employee stock purchase plan.
TELA Bio, Inc. reported several equity transactions by Chief Technology Officer Paul Talmo. On February 20, 2026, he received awards of 57,000 shares of common stock and 85,000 stock options, each at a grant price of $0.00 per share.
The stock award consists of restricted stock units that vest in four equal annual installments beginning on February 20, 2027, subject to continuous service. The option vests 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months.
On February 21 and 23, 2026, the company withheld 3,385 and 4,061 shares of common stock, respectively, at prices of $0.7174 and $0.766 per share to cover tax liabilities upon RSU vesting. After these transactions, Talmo directly held 173,436 shares of common stock and 85,000 stock options.
TELA Bio, Inc. executive Roberto Cuca, the COO and CFO, reported a mix of equity awards and tax-related share withholdings. On February 20, 2026, he received a grant of 85,000 stock options and an award of 57,000 shares of common stock, both as direct ownership. The options vest over four years starting February 20, 2027, and the share award consists of RSUs vesting in four equal annual installments beginning the same date, subject to continued service.
To cover withholding taxes on RSU vesting, the issuer withheld 4,780 shares on February 21, 2026 at $0.7174 per share and 5,234 shares on February 23, 2026 at $0.7660 per share, characterized as tax-withholding dispositions rather than open-market sales. After these transactions, Cuca directly owned 257,377 shares of common stock.
TELA Bio, Inc. President Jeffrey Blizard reported equity awards consisting of stock options and restricted stock units granted on February 20, 2026. He was granted stock options for 127,000 shares at an exercise price of $0.00 per share and a separate award of 86,000 shares of common stock in the form of restricted stock units.
The restricted stock units will vest in four equal annual installments beginning on February 20, 2027, contingent on his continuous service through each vesting date. The stock option will vest 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, also subject to continued service.
TELA Bio, Inc. Chief Accounting Officer Megan Smeykal reported multiple equity transactions involving the company’s common stock. On February 18, 2026, she acquired 32,850 shares through a grant of restricted stock units (RSUs) at a stated price of $0.0000 per share. According to the footnotes, these RSUs vest in four equal annual installments beginning on February 18, 2027, contingent on her continued service.
On February 19, 21, and 23, 2026, shares of common stock were disposed of in three separate transactions coded “F,” each described as a tax-withholding disposition to satisfy withholding taxes upon RSU vesting. After the latest transaction, her direct holdings stood at 66,873 shares of common stock.
TELA Bio is registering up to 2,000,000 shares of common stock for resale by Perceptive Credit Holdings V, LP, issuable upon exercise of a warrant connected to a November 2025 credit agreement. These shares may be sold from time to time on Nasdaq or in private transactions at market or negotiated prices, with the selling stockholder paying its own selling commissions while TELA covers registration expenses. TELA will not receive proceeds from any resale of these shares, but could receive cash if the warrant is exercised, which it currently plans to use for general corporate purposes such as sales and marketing, research and development, working capital and capital spending.
TELA Bio is a commercial-stage medical technology company focused on soft-tissue reconstruction, led by its OviTex hernia repair and OviTex PRS plastic and reconstructive surgery product portfolios. The company cites an estimated U.S. addressable market of about $1.8 billion for OviTex and $800 million for OviTex PRS. A key risk highlighted is that future sales of these registered shares by the selling stockholder, or the perception that such sales may occur, could put downward pressure on TELA’s stock price.